250
Participants
Start Date
April 25, 2024
Primary Completion Date
May 31, 2026
Study Completion Date
April 30, 2027
QLC1101
QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors.
NOT_YET_RECRUITING
Harbin Medical university cancer hospital, Harbin
RECRUITING
Shanghai east hospital, Shanghai
NOT_YET_RECRUITING
Jiangxi Cancer Hospital, Nanchang
NOT_YET_RECRUITING
The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou
NOT_YET_RECRUITING
Yunnan Cancer Hospital, Kunming
Qilu Pharmaceutical Co., Ltd.
INDUSTRY